The device (TriGuard 3, Keystone Heart) showed potential to prevent larger ischemic brain lesions, Jeffrey W. Moses, MD, professor of medicine and director of interventional therapeutics at ...

Stroke remains a problem after TAVR and continues to feed discussions around how extensively cerebral embolic protection devices and other strategies should be used. In a session during TVT Connect, ...

Emerging data for two latest-generation transcatheter aortic valve prostheses in the setting of failed surgical valves are “reassuring,” according to late-breaking clinical science presentations at ...

The first day at the recently concluded Transcatheter Cardiovascular Therapies (TCT) meeting in Washington, D.C., was reportedly heavily focused on TAVR - transcatheter aortic valve replacement ...

Atlanta — A randomized transcatheter aortic valve replacement (TAVR) trial demonstrated that a self-expanding device performs better on multiple prognostically important measures of valve function at ...

CHICAGO -- Tweaks made to Medtronic's CoreValve transcatheter heart valve (THV) line in the last few years have tracked with some improved outcomes after transcatheter aortic valve replacement (TAVR), ...

(Reuters) - Edwards Lifesciences said on Thursday it would spin off its critical care unit at the end of 2024 to concentrate on its larger heart devices business. Transcatheter aortic valve ...

The potential is high for TAVR adoption in emerging markets, according to Venkat Rajan, an analyst at Frost & Sullivan. “It is, however, coming in at a higher price point than traditional valves,” he ...

A device designed to remove embolic material—fragments of tissue that can be released into the bloodstream during transcatheter aortic valve replacement (TAVR)—did not result in a reduction in the ...

PHOENIX -- The newer generation Evolut transcatheter aortic valve replacement (TAVR) device improved on procedural and possibly safety characteristics, the TVT registry showed. The Evolut FX device ...

Medtronic plc’s Evolut Low-Risk trial continued to show non-inferiority of transcatheter aortic valve replacement to surgical aortic valve replacement in terms of death or disabling stroke at five ...